Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Haisco-USA Pharmaceuticals, Inc.
483
•Haisco-USA Pharmaceuticals, Inc.•October 9, 2025

Haisco-USA Pharmaceuticals, Inc. – FDA 483, Oct 9, 2025

Record Details

During an inspection conducted from September 29 to October 9, 2025, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Haisco-USA Pharmaceuticals, Inc. at its Bridgewater, NJ corporate headquarters. The primary observation highlighted the firm's failure to ensure proper monitoring of a clinical study, specifically the protocol titled "(b)(4)". This lapse resulted in inadequate data verification by their contract research organization (CRO), leading to the enrollment of study subjects who did not meet established protocol inclusion and exclusion criteria.

Examples cited by the FDA included multiple subjects across different sites whose screening vital signs, such as heart rate or systolic blood pressure, were outside the defined eligibility thresholds. Despite these discrepancies in source data, the CRO monitor had verified these subjects as meeting all criteria during routine monitoring visits. This indicates a significant oversight in ensuring the study's adherence to its investigational plan. While an FDA Form 483 lists observations and is not a final determination of compliance, Haisco-USA Pharmaceuticals, Inc. is expected to address these findings and implement corrective actions to ensure regulatory adherence, particularly concerning clinical trial oversight and data integrity under the Federal Food, Drug, and Cosmetic Act.

Company
Haisco-USA Pharmaceuticals, Inc.
Inspection date
October 9, 2025
Product type
drugs
Office
Division of Pharmaceutical Quality Operations I
Person
  • Mayar M. Mussa
View Company Profile

ID · 31653e03-5bdd-4028-9de5-af07af014694

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Haisco-USA Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.